Stevens-Johnson syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:
{{Stevens-Johnson syndrome}}
{{Stevens-Johnson syndrome}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{AHS}}
==Overview==
==Overview==
SJS is a rare condition, with a reported incidence of around 2-7 per 1000,000 people per year and a mean mortality rate of 4.8 percent. It is seen in patients of all age groups but particularly in children and young adults. Females are more commonly affected than males


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence of SJS is approximately 2-7 per 1000,000 individuals per year.<ref name="pmid2036028">{{cite journal| author=Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M et al.| title=A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures. | journal=Arch Dermatol | year= 1991 | volume= 127 | issue= 6 | pages= 831-8 | pmid=2036028 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2036028  }}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The incidences of SJS, SJS-TEN, and TEN were found to be a mean 5.3, 0.8, and 0.4 cases per million children per year in the US<ref name="pmid28285784">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI| title=Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. | journal=J Am Acad Dermatol | year= 2017 | volume= 76 | issue= 5 | pages= 811-817.e4 | pmid=28285784 | doi=10.1016/j.jaad.2016.12.024 | pmc=5502094 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28285784  }}</ref>
 
*The mean estimated incidences of SJS, SJS/TEN, and TEN were found to be 9.2, 1.6, and 1.9 per million adults per year in the US<ref name="pmid27039263">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Silverberg JI| title=Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. | journal=J Invest Dermatol | year= 2016 | volume= 136 | issue= 7 | pages= 1387-1397 | pmid=27039263 | doi=10.1016/j.jid.2016.03.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27039263  }}</ref>
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*Between years 2009-2012, the Mean adjusted mortality was 4.8% for SJS, 19.4% for SJS/TEN, and 14.8% for TEN<ref name="pmid270392632">{{cite journal| author=Hsu DY, Brieva J, Silverberg NB, Silverberg JI| title=Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. | journal=J Invest Dermatol | year= 2016 | volume= 136 | issue= 7 | pages= 1387-1397 | pmid=27039263 | doi=10.1016/j.jid.2016.03.023 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27039263  }}</ref>
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may develop SJS.
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*The incidence of SJS might be higher in Non White/Multiracial people as compared to White{{cite web |url=https://doi.org/10.1016/j.jid.2016.03.023 |title=Redirecting |format= |work= |accessdate=}}
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Women are more commonly affected by SJS than males{{cite web |url=https://doi.org/10.1016/j.jid.2016.03.023 |title=Redirecting |format= |work= |accessdate=}}.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Latest revision as of 21:38, 29 August 2018

Stevens-Johnson syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stevens-Johnson Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stevens-Johnson syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stevens-Johnson syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stevens-Johnson syndrome epidemiology and demographics

CDC on Stevens-Johnson syndrome epidemiology and demographics

Stevens-Johnson syndrome epidemiology and demographics in the news

Blogs on Stevens-Johnson syndrome epidemiology and demographics

Directions to Hospitals Treating Stevens-Johnson syndrome

Risk calculators and risk factors for Stevens-Johnson syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anila Hussain, MD [2]

Overview

SJS is a rare condition, with a reported incidence of around 2-7 per 1000,000 people per year and a mean mortality rate of 4.8 percent. It is seen in patients of all age groups but particularly in children and young adults. Females are more commonly affected than males

Epidemiology and Demographics

Incidence

  • The incidence of SJS is approximately 2-7 per 1000,000 individuals per year.[1]
  • The incidences of SJS, SJS-TEN, and TEN were found to be a mean 5.3, 0.8, and 0.4 cases per million children per year in the US[2]
  • The mean estimated incidences of SJS, SJS/TEN, and TEN were found to be 9.2, 1.6, and 1.9 per million adults per year in the US[3]

Case-fatality rate/Mortality rate

  • Between years 2009-2012, the Mean adjusted mortality was 4.8% for SJS, 19.4% for SJS/TEN, and 14.8% for TEN[4]

Age

  • Patients of all age groups may develop SJS.

Race

  • The incidence of SJS might be higher in Non White/Multiracial people as compared to White"Redirecting".

Gender

  • Women are more commonly affected by SJS than males"Redirecting"..

References

  1. ↑ Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M; et al. (1991). "A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures". Arch Dermatol. 127 (6): 831–8. PMID 2036028.
  2. ↑ Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI (2017). "Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States". J Am Acad Dermatol. 76 (5): 811–817.e4. doi:10.1016/j.jaad.2016.12.024. PMC 5502094. PMID 28285784.
  3. ↑ Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.
  4. ↑ Hsu DY, Brieva J, Silverberg NB, Silverberg JI (2016). "Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults". J Invest Dermatol. 136 (7): 1387–1397. doi:10.1016/j.jid.2016.03.023. PMID 27039263.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Stevens-Johnson_syndrome_epidemiology_and_demographics&oldid=1492568"